Blinatumomab is a tandem single-chain fragment variable (scFv) targeting CD19 on B cells of acute lymphoblastic leukemia (ALL) patients and links them via its CD3 binding moiety to cytotoxic T cells (3). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.